ASH 2023 | The issue of short-lived treatment responses in heavily pretreated patients with ALL
Britta Vormoor
• 10 Dec 2023
Britta Vormoor, MD, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands, discusses the issue of short-lived treatment responses in heavily pretreated patients with acute lymphoblastic leukemia (ALL). With reference to a Phase I/II trial (NCT03705507), Dr Vormoor explains that patients must be in a deep enough remission to consider transplantation or consolidation with therapies such as CAR T-cells. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
